Morgan Stanley & Co. International Plc - Net Worth and Insider Trading

Morgan Stanley & Co. International Plc Net Worth

The estimated net worth of Morgan Stanley & Co. International Plc is at least $143 Million dollars as of 2024-09-28. Morgan Stanley & Co. International Plc is the 2105 Underwriter of Shenzhen Hepalink Pharmaceutical Group Co Ltd and owns about 38,215,400 shares of Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) stock worth over $143 Million. Details can be seen in Morgan Stanley & Co. International Plc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Morgan Stanley & Co. International Plc has not made any transactions after 2020-07-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Morgan Stanley & Co. International Plc

Morgan Stanley & Co. International Plc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Morgan Stanley & Co. International Plc owns 1 companies in total, including Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) .

Click here to see the complete history of Morgan Stanley & Co. International Plc’s form 4 insider trades.

Insider Ownership Summary of Morgan Stanley & Co. International Plc

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:09989	Shenzhen Hepalink Pharmaceutical Group Co Ltd	2020-07-08	2105 Underwriter

Morgan Stanley & Co. International Plc Latest Holdings Summary

Morgan Stanley & Co. International Plc currently owns a total of 1 stock. Morgan Stanley & Co. International Plc owns 38,215,400 shares of Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) as of July 8, 2020, with a value of $143 Million.

Latest Holdings of Morgan Stanley & Co. International Plc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:09989	Shenzhen Hepalink Pharmaceutical Group Co Ltd	2020-07-08	38,215,400	3.74	142,925,596

Holding Weightings of Morgan Stanley & Co. International Plc

Morgan Stanley & Co. International Plc Form 4 Trading Tracker

According to the SEC Form 4 filings, Morgan Stanley & Co. International Plc has made a total of 2 transactions in Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Shenzhen Hepalink Pharmaceutical Group Co Ltd is the sale of 38,215,400 shares on July 8, 2020, which brought Morgan Stanley & Co. International Plc around $0.

Insider Trading History of Morgan Stanley & Co. International Plc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Morgan Stanley & Co. International Plc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Morgan Stanley & Co. International Plc Ownership Network

Ownership Network List of Morgan Stanley & Co. International Plc

No Data

Ownership Network Relation of Morgan Stanley & Co. International Plc

Morgan Stanley & Co. International Plc Owned Company Details

What does Shenzhen Hepalink Pharmaceutical Group Co Ltd do?

Who are the key executives at Shenzhen Hepalink Pharmaceutical Group Co Ltd?

Morgan Stanley & Co. International Plc is the 2105 Underwriter of Shenzhen Hepalink Pharmaceutical Group Co Ltd. Other key executives at Shenzhen Hepalink Pharmaceutical Group Co Ltd include 2101 Beneficial owner hong ze jun , 2102 Investment manager Orbimed Capital Llc , and 2201 Interest of corporation controlled by you Morgan Stanley International Holdings Inc. .

Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) Insider Trades Summary

Over the past 18 months, Morgan Stanley & Co. International Plc made no insider transaction in Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989). Other recent insider transactions involving Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) include a net purchase of 670,000 shares made by hong ze jun ,

In summary, during the past 3 months, insiders sold 0 shares of Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) were sold and 670,000 shares were bought by its insiders, resulting in a net purchase of 670,000 shares.

Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989)'s detailed insider trading history can be found in Insider Trading Tracker table.

Shenzhen Hepalink Pharmaceutical Group Co Ltd Insider Transactions

No Available Data

Morgan Stanley & Co. International Plc Mailing Address

Above is the net worth, insider trading, and ownership report for Morgan Stanley & Co. International Plc. Currently GuruFocus does not have mailing address information for Morgan Stanley & Co. International Plc.

Discussions on Morgan Stanley & Co. International Plc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.